SOLUTION

SOLUTION
The World Health Organization defines a ‘rare disease’ as any medical condition, with a specific pattern of clinical signs, symptoms, and findings that affects fewer than or equal to 1 in 2,000 persons living in any WHO-defined world region. Although instances of these ‘rare diseases’, particularly genetic disorders, are – by their very nature – ‘rare’ when considered on an individual basis, there are numerous and diverse conditions.
Rare diseases include, but are not limited to, rare genetic diseases, rare cancers, rare infectious diseases, rare poisonings, rare immune-related diseases, rare idiopathic diseases, and rare undetermined conditions.
The International Statistical Classification of Diseases and Related Health Problems (ICD) ICD-11 classification includes some 5,500 rare diseases and their synonyms. Rare diseases affect approximately 6% of people worldwide, which, when extrapolated to the 2022 global population is equivalent to more than 470 million people.
At Jameel Health we’re proud to have expanded our ability to bring treatments in this area to the Global South through our recent acquisition of Genpharm, in 2023.
Genpharm provides fast-track market access to rare disease and specialty pharmaceutical companies looking to expand into the Middle East and North Africa and Türkiye. It is the regional leader in rare diseases and one of the only regional companies to have gene therapy expertise.
Founded in 2012, it, has bases in the Dubai Science Park, UAE, an office in Boston, USA, in the heart of the biotech hub, and in Ireland. Operating through evidence-based medicine and the highest ethical standards, Genpharm provides its partners with fast and sustainable market access solutions into the MENA region.
In 2023, following its 10th anniversary year, Jameel Health acquired Genpharm expanding our distribution infrastructure and also portfolio with Genpharm’s specialism in rare disease therapies.
Visit: Genpharm
For most of human history, even the tiniest of scratches could prove fatal. Never mind pneumonia, childbirth or surgery, gardening was a potentially deadly pursuit. A graze or scratch could become …
Healthcare – or rather adequate access to it – is one of the biggest challenges facing society today.
Despite the unprecedented levels of global wealth created by economic development over the past century, millions of people across vast regions of our planet are dying unnecessarily through poor …
The COVID-19 pandemic has been a stark reminder – if any were needed – of humankind’s persistent failure to address one of its most enduring, and potentially destabilizing, challenges – …
Health technology is transforming the way we can diagnose, treat and prevent disease, and has the potential to radically improve access to healthcare on a global scale.
From a longer-term historical perspective, the world we live in is undoubtedly fairer than it has ever been versus, say 100 years ago. In many – if not the majority – of countries across the …
Jameel Health appoints three globally respected scientists as special scientific advisors to join its mission in accelerating access to modern medical care across the global south.
©️ 2020-2023, Meddist Company Limited (Jameel Health). All rights in this Site are fully reserved. Permission to use this site is granted strictly subject to the Terms of Use. The Abdul Latif Jameel name, Jameel Health name; the Abdul Latif Jameel and Jameel Health logotypes and pentagon-shaped graphic are trademarks, or registered trademarks of Abdul Latif Jameel IPR Company Limited.
For medical incidence reporting please email: safety@jameelhealth.com or call +971 4 448 0905